LIPISENSE Trademark

Trademark Overview

On Thursday, July 27, 2023, a trademark application was filed for LIPISENSE with the United States Patent and Trademark Office. The USPTO has given the LIPISENSE trademark a serial number of 79380504. The federal status of this trademark filing is REGISTERED as of Tuesday, August 27, 2024. This trademark is owned by Lipigon Pharmaceuticals AB. The LIPISENSE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of hyperlipidemia
lipisense

General Information

Serial Number79380504
Word MarkLIPISENSE
Filing DateThursday, July 27, 2023
Status700 - REGISTERED
Status DateTuesday, August 27, 2024
Registration Number7484171
Registration DateTuesday, August 27, 2024
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, June 11, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of hyperlipidemia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 13, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLipigon Pharmaceuticals AB
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressSE
Party NameLipigon Pharmaceuticals AB
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSE
Party NameLipigon Pharmaceuticals AB
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSE

Trademark Events

Event DateEvent Description
Wednesday, April 10, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, April 27, 2024REFUSAL PROCESSED BY MPU
Thursday, October 12, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, October 13, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 17, 2023APPLICATION FILING RECEIPT MAILED
Friday, March 29, 2024ASSIGNED TO EXAMINER
Tuesday, April 9, 2024NON-FINAL ACTION WRITTEN
Saturday, April 27, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, May 7, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 7, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 7, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 11, 2024PUBLISHED FOR OPPOSITION
Wednesday, May 22, 2024REFUSAL PROCESSED BY IB
Wednesday, May 22, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 27, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 11, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, November 29, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 27, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Thursday, March 27, 2025NEW REPRESENTATIVE AT IB RECEIVED
Friday, April 4, 2025FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, April 4, 2025NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, March 11, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Saturday, February 15, 2025FINAL DISPOSITION NOTICE SENT TO IB
Saturday, February 15, 2025FINAL DISPOSITION PROCESSED
Tuesday, March 11, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

Related Keywords

lipisense hyperlipidemia treatment preparations pharmaceutical